HeidelbergCapital is an independent Private Equity Funds Group, specialising in Secondary Direct Investments, e.g. the acquisition of shareholdings in companies previously held by private equity/venture capital funds or banks.
vasopharm completes patient enrollment for Phase III Traumatic Brain Injury Trial (NOSTRA)
4SC: Positive DSMB safety review of 4SC’s pivotal RESMAIN study of resminostat in CTCL
Nanogate SE Expects 2018 Operating Result (EBITDA) of More Than EUR 24 Million and Sales of at Least EUR 220 Million
4SC AG strengthens patent protection for its Hedgehog/GLI signaling inhibitor 4SC-208
Nanogate SE: Market Launch of New Technology Platform to Replace Stainless Steel
HeidelbergCapital was founded mid 2007. The company is jointly managed by Dr. Clemens Doppler and Prof. Dr. Martin Weiblen, former Managing Director of a multi-billion family office in London/U.K. and advisor to several Life Science-Funds. Dr. Clemens Doppler is a former Partner at 3i, the British Private Equity Group. The New York based Private Equity Investor Auda has committed c150m USD for the first fund, HeidelbergCapital Private Equity Fund I.
The portfolio of HeidelbergCapital ranges from investments in later stage venture companies with a proven business model to established mid-size operations. As an active partner, HeidelbergCapital supports the companies in strategic business decisions, but also provides, where appropriate, funding for further growth.